Views
1 year ago

2013 Scientific Report

  • Text
  • Report
  • Institute
  • Clinical
  • Molecular
  • Scientific
  • Tumor
  • Laboratory
  • Signaling

Giselle S. Sholler, M.D.

Giselle S. Sholler, M.D. Laboratory of Neuroblastoma Translational Research Dr. Sholler received her M.S. in microbiology and immunology from McGill University, Montreal, Quebec, and her M.D. from New York Medical College. She worked in the Division of Pediatric Hematology/Oncology at the University of Vermont before joining VAI in 2011 as Associate Professor and Co-Director of the Pediatric Oncology Program. Dr. Sholler has a joint appointment with the Helen DeVos Children’s Hospital as the Haworth Family Director of the Innovative Therapeutics Clinic in the Division of Pediatric Oncology. From left: Sholler, Ellis, Dutta, Vander Werff, McClung, Bender, Eckardt, Kendzicky, Zhao Staff Mary Bender, RN Genevieve Bergendahl, RN, B.S.N. Akshita Dutta, M.S. Alexandra Eckardt, B.S. Ellen Ellis Ann Kendzicky, B.S. Heather McClung, Ph.D. Alyssa Vander Werff, M.S. Ping Zhao, Ph.D. 47

Van Andel Research Institute | Scientific Report Research Interests Our laboratory is committed to pushing forward cures for childhood cancers by identifying and exploiting new therapies for neuroblastoma and medulloblastoma, which continue to be therapeutic challenges in pediatrics. Our research aims at understanding the specific biological and genomic profiles of patients and using the information from patient-derived xenograft models and laboratory studies to identify and deliver new therapies to, and improve outcomes for, children with relapsed disease. Through the Neuroblastoma and Medulloblastoma Translational Research Consortium, which Dr. Sholler chairs, clinical trials are being conducted, for example, on molecular guided therapy for refractory/recurrent neuroblastoma and on a-diflouromethylornithine (DFMO) for patients with high-risk neuroblastoma in remission. Recent Publications Eslin, Don, Umesh T. Sankpal, Chris Lee, Robert M. Sutphin, Pius Maliakal, Erika Currier, Giselle Sholler, Moeez Khan, and Riyaz Basha. In press. Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: a novel therapeutic agent for neuroblastoma. Molecular Carcinogenesis. Sholler, Giselle L. Saulnier, William Ferguson, Genevieve Bergendahl, Erika Currier, Shannon R. Lenox, Jeffrey Bond, Marni Slavik, William Roberts, Deanna Mitchell, Don Eslin, et al. In press. A pilot trial testing the feasibility of using molecularguided therapy in patients with recurrent neuroblastoma. Journal of Cancer Therapy. Sun, Yujing, Girja Shukla, Stephanie C. Pero, Erika Currier, Giselle Sholler, and David Krag. 2012. Single tumor imaging with multiple antibodies targeting different antigens. BioTechniques Rapid Dispatches, doi 10.2144/000113855. 48

Publications by Year